
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc is advancing its product candidate, lorundrostat, which has demonstrated a significant potential to improve blood pressure management, showing a placebo-adjusted benefit of over 10mmHg, a key metric that resonates positively with prescribers. The company's robust profile in addressing uncontrolled and resistant hypertension, along with anticipated FDA feedback and a near-term NDA submission, suggests promising commercial prospects. Additionally, feedback from key opinion leaders (KOLs) indicates a growing patient need for innovative treatments, leading to an increase in estimated market uptake from 10% to 12% among patients diagnosed with uncontrolled hypertension.
Bears say
The financial outlook for Mineralys Therapeutics Inc. remains negative due to several significant risks, including the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates influenced by market size, penetration rates, and pricing challenges. Additionally, the company faces the risk of inadequate capital resources necessary to fund its operations, which could hinder continued program development and commercialization efforts. Concerns surrounding patient safety, particularly regarding potassium levels and the implications of potential regulatory cutoff adjustments, further exacerbate the company's investment risks.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares